The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial.
The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
“Tykerb has failed to establish itself as a strong competitor in the HER2 positive market, and its use in the adjuvant setting was the only way it could gain a decent share of the breast cancer therapeutics market after Roche launched Perjeta and Kadcyla,” said GlobalData analyst Jamie Mallinson, Ph.D.
This failure indicates that there is “little more to expect from Tykerb”. GlobalData believes that neither GSK nor Novartias, who bought GSK’s oncology portfolio in April, will spend significant efforts in marketing the drug further.
Mallinson added: “For now, the pharmaceutical industry keenly awaits the results of the adjuvant Perjeta clinical trial, APHINITY, with preliminary DFS data expected in 2016.”
Perjeta was approved for use in the neoadjuvant setting by the FDA in 2013.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.